<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83002">
  <stage>Registered</stage>
  <submitdate>22/07/2008</submitdate>
  <approvaldate>1/08/2008</approvaldate>
  <actrnumber>ACTRN12608000381381</actrnumber>
  <trial_identification>
    <studytitle>Comparing bioequivalence of oral cholecalciferol and ergocalciferol treatment for 3 months in Australian hip fracture cases</studytitle>
    <scientifictitle>A three month prospective study of elderly australian hip fracture patients treated with ergocalciferol compared with cholecalciferol therapy: The vitamin D outcome study</scientifictitle>
    <utrn />
    <trialacronym>VDOS</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D deficiency</healthcondition>
    <healthcondition>Hip fractures</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ergocalciferol 1000 IU daily oral therapy plus matching placebo (sugar pills) daily and taken at the same time for 3 months</interventions>
    <comparator>Cholecalciferol 1000 IU daily oral therapy plus matching oral placebo (sugar capsule) daily and taken at the same time for 3 months</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Increase in 25 hydroxyvitamin D as measured by high performance liquid chromatography</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in 1,25 dihydroxyvitamin D as measured by radioimmunoassay</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in 25-hydroxyvitamin D as measured by radioimmunoassay</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in parathyroid hormone</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in vitamin D binding protein</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in 25 OHD as measured by diasorin Radioimunoassay</outcome>
      <timepoint>Single measurement at baseline and on completion of 3 months study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hip fracture
Residing in Perth metropolitan area</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Ionised hypercalcemia
History of thyrotoxicosis/Cushings in last 2 years
Anticonvulsant medication use
Current or within last 3 months use of estrogen, raloxifene, calcitriol, anabolic steroids, bisphosphonates, sodium fluoride or corticosteroids
Renal failre as defined by serum creatinine &gt; 150 umol/L
Patients unlikely to comply or live longer than 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Block randomistation of eligible patients by RPH pharmacy. Allocation concealment was attained by using numbered containers, central randomisation by phone/fax at RPH pharmacy by a pharmacist who was not otherwise involved in the trial.</concealment>
    <sequence>Block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Maching placebo tablets used to ensure patients and researchers are blinded to treatment assignment.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>3/09/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Medical Research Foundation</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Wellington Street
Perth 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Medical Research Foundation</fundingname>
      <fundingaddress>Royal Perth Hospital
Wellington Street
Perth 6000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Approximately 100 hip fracture cases are expected to be recruited over a 12 month period who are vitamin D insufficient, reside in the Perth metropolitan area, consent to inclusion in the trial and dont fulfill any exclusion citeria.  Vitamin D insufficiency will be defined as a 25 OHD &lt; 50 nmol/L and initially measured using our current assay (Diasorin 25OHD radioimmunoassay).  In a randomised fashion all vitamin D insufficient patients will be offered standard therapy with Ostelin 1000 I.U./day (ergocalciferol) or Vigantoletten 1000 I.U./day (Cholecalciferol obtained from Merck, Germany) in addition to matching placebo to prevent unblinding of study design.   Those patients consenting to trial entry will have serum collected for intact PTH, whole PTH, ionised calcium, vitamin D binding protein and 1,25 dihydroxyvitamin D at baseline and following three months therapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Box X2213
GPO Perth 6847</ethicaddress>
      <ethicapprovaldate>12/03/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Paul Glendenning</name>
      <address>Royal Perth Hospital
Wellington Street
Perth 6000</address>
      <phone>08 9224 2421</phone>
      <fax />
      <email>Paul.Glendenning@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Paul Glendenning</name>
      <address>Department of Core CLinical Pathology and Biochemistry
Royal Perth Hospital
Wellington Street
Perth 6000</address>
      <phone>08 9224 2421</phone>
      <fax />
      <email>Paul.Glendenning@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Paul Glendenning</name>
      <address>Department of Core Clinical Pathology and Biochemistry
Royal Perth Hospital
Wellington Street
Perth 6000</address>
      <phone>08 9224 2421</phone>
      <fax />
      <email>Paul.Glendenning@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>